Summarized by Masters of Longevity from Startupticker.ch.
Nouscom’s fundraising and trial update make for a biotech financing and clinical-development brief, useful for investors and industry-watchers.
Key Takeaways
- Nouscom raised $135 million in a Series D round co-led by M Ventures and Revelation Partners.
- Phase 1b/2 data showed all evaluable Lynch Syndrome carriers dosed with NOUS-209 remained free of advanced adenomas and colorectal cancer after years 1 and 2.
- FDA granted Fast Track designation and proceeds will fund a single global registration‑enabling cancer interception trial for Lynch Syndrome carriers.
